{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:24:19Z","timestamp":1790742259950,"version":"4.1.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000828","name":"Royal Society of Medicine","doi-asserted-by":"publisher","award":["IES\\R3\\213131"],"award-info":[{"award-number":["IES\\R3\\213131"]}],"id":[{"id":"10.13039\/501100000828","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["Challenge Award"],"award-info":[{"award-number":["Challenge Award"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Clinical Research Career Development Fellowship"],"award-info":[{"award-number":["Clinical Research Career Development Fellowship"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease requiring additional therapeutic strategies. MCL1, an anti-apoptotic BCL2 family member, promotes cancer-cell survival, but its role in mCRPC remains poorly understood. Here, we characterise MCL1 in multiple mCRPC biopsy cohorts and patient-derived models, assessing responses to MCL1 inhibition. <jats:italic>MCL1<\/jats:italic> copy number gain (14%\u201334%) correlates with increased MCL1 expression and worse outcomes. MCL1 inhibition exhibits anti-tumour effects in <jats:italic>MCL1<\/jats:italic>-gained mCRPC models. Co-inhibition of MCL1 and AKT induces cancer-specific cell death in PTEN-loss\/PI3K-activated models in vitro and in vivo, modulating BAD-BCLXL and BIM-MCL1 interactions, with durable anti-tumour activity in models with AKT inhibitor acquired resistance. Finally, CDK9-mediated MCL1 downregulation combined with AKT inhibition recapitulates these findings, providing further opportunities for clinical translation. These data support early phase clinical trials targeting MCL1, both as monotherapy for <jats:italic>MCL1<\/jats:italic>-gained mCRPC, and in combination with AKT inhibition for PTEN-loss\/PI3K-activated mCRPC.<\/jats:p>","DOI":"10.1038\/s41467-025-64042-5","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:03:01Z","timestamp":1759914181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Juan M.","family":"Jim\u00e9nez-Vacas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Westaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2754-5608","authenticated-orcid":false,"given":"Ines","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"De Haven Brandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Padilha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8004-1846","authenticated-orcid":false,"given":"Wei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1105-1781","authenticated-orcid":false,"given":"George","family":"Seed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisa","family":"Bogdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5018-8078","authenticated-orcid":false,"given":"Bora","family":"Gurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bertan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5936-2706","authenticated-orcid":false,"given":"Susana","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryou","family":"Lambros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1948-7512","authenticated-orcid":false,"given":"Antonio J.","family":"Montero-Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilsa","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Pak Lok","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Buroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4101-1502","authenticated-orcid":false,"given":"Wanting","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje J.","family":"Neeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Welti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5207-3864","authenticated-orcid":false,"given":"Jan","family":"Rekowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Paravati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Gabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Pandell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4043-8296","authenticated-orcid":false,"given":"Mateus","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Riisnaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souvik","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Waldron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Hobern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Bernett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Liodaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Persse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7961-7430","authenticated-orcid":false,"given":"Patricia","family":"Galipeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2613-8425","authenticated-orcid":false,"given":"Scott","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shana Y.","family":"Trostel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3244-1332","authenticated-orcid":false,"given":"Fatima","family":"Karzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6928-3833","authenticated-orcid":false,"given":"Cindy H.","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L.","family":"Beatson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6646-6132","authenticated-orcid":false,"given":"Carleen","family":"Klumpp-Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Varkaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul M.","family":"Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8666-1608","authenticated-orcid":false,"given":"Amanda","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0957-6279","authenticated-orcid":false,"given":"Florence","family":"Raynaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7399-5844","authenticated-orcid":false,"given":"Nathan A.","family":"Lack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9386-9001","authenticated-orcid":false,"given":"Craig J.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7578-7272","authenticated-orcid":false,"given":"Gavin","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2428-5613","authenticated-orcid":false,"given":"William D.","family":"Figg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2760-1853","authenticated-orcid":false,"given":"Adam G.","family":"Sowalsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5451-5726","authenticated-orcid":false,"given":"Peter S.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5077-5379","authenticated-orcid":false,"given":"Suzanne","family":"Carreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4546-7371","authenticated-orcid":false,"given":"Steven P.","family":"Balk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2034-595X","authenticated-orcid":false,"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3740-1612","authenticated-orcid":false,"given":"Adam","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"64042_CR1","doi-asserted-by":"publisher","first-page":"e0227552","DOI":"10.1371\/journal.pone.0227552","volume":"15","author":"J Mehtala","year":"2020","unstructured":"Mehtala, J. et al. Overall survival and second primary malignancies in men with metastatic prostate cancer. PLoS One 15, e0227552 (2020).","journal-title":"PLoS One"},{"key":"64042_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.clgc.2016.08.018","volume":"15","author":"DM Moreira","year":"2017","unstructured":"Moreira, D. M. et al. Predicting time from metastasis to overall survival in castration-resistant prostate cancer: results from search. Clin. Genitourin. Cancer 15, 60\u201366.e2 (2017).","journal-title":"Clin. Genitourin. Cancer"},{"key":"64042_CR3","doi-asserted-by":"crossref","unstructured":"Sumanasuriya S., De Bono J. Treatment of advanced prostate cancer-a review of current therapies and future promise. Cold Spring Harb. Perspect. Med. 8, a030635 (2018).","DOI":"10.1101\/cshperspect.a030635"},{"key":"64042_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"64042_CR5","doi-asserted-by":"crossref","unstructured":"Westaby, D. et al. Targeting the intrinsic apoptosis pathway: a window of opportunity for prostate cancer. Cancers. 14, 51 (2021).","DOI":"10.3390\/cancers14010051"},{"key":"64042_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"Carneiro, B. A. & El-Deiry, W. S. Targeting apoptosis in cancer therapy. Nat. Rev. Clin. Oncol. 17, 395\u2013417 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"64042_CR7","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899\u2013905 (2010).","journal-title":"Nature"},{"key":"64042_CR8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/s42003-021-02564-6","volume":"4","author":"H Widden","year":"2021","unstructured":"Widden, H. & Placzek, W. J. The multiple mechanisms of MCL1 in the regulation of cell fate. Commun. Biol. 4, 1029 (2021).","journal-title":"Commun. Biol."},{"key":"64042_CR9","doi-asserted-by":"publisher","first-page":"6105","DOI":"10.18632\/oncotarget.3368","volume":"6","author":"FR Santer","year":"2015","unstructured":"Santer, F. R. et al. Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy. Oncotarget 6, 6105\u20136122 (2015).","journal-title":"Oncotarget"},{"key":"64042_CR10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.18632\/oncoscience.231","volume":"2","author":"T Reiner","year":"2015","unstructured":"Reiner, T. et al. Mcl-1 protects prostate cancer cells from cell death mediated by chemotherapy-induced DNA damage. Oncoscience 2, 703\u2013715 (2015).","journal-title":"Oncoscience"},{"key":"64042_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29824-1","volume":"13","author":"M Troiani","year":"2022","unstructured":"Troiani, M. et al. Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer. Nat. Commun. 13, 2177 (2022).","journal-title":"Nat. Commun."},{"key":"64042_CR12","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/s41586-023-06696-z","volume":"623","author":"C Guo","year":"2023","unstructured":"Guo, C. et al. Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. Nature 623, 1053\u20131061 (2023).","journal-title":"Nature"},{"key":"64042_CR13","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccr.2012.02.028","volume":"21","author":"G Wei","year":"2012","unstructured":"Wei, G. et al. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell 21, 547\u2013562 (2012).","journal-title":"Cancer Cell"},{"key":"64042_CR14","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1158\/0008-5472.CAN-11-3603","volume":"72","author":"KC Goldsmith","year":"2012","unstructured":"Goldsmith, K. C. et al. Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. Cancer Res. 72, 2565\u20132577 (2012).","journal-title":"Cancer Res."},{"key":"64042_CR15","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/pros.23843","volume":"79","author":"AB Pilling","year":"2019","unstructured":"Pilling, A. B. & Hwang, C. Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide. Prostate 79, 1347\u20131359 (2019).","journal-title":"Prostate"},{"key":"64042_CR16","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-18-0549","volume":"24","author":"S Arai","year":"2018","unstructured":"Arai, S. et al. Tyrosine Kinase inhibitors increase MCL1 degradation and in combination with BCLXL\/BCL2 inhibitors drive prostate cancer apoptosis. Clin. Cancer Res. 24, 5458\u20135470 (2018).","journal-title":"Clin. Cancer Res."},{"key":"64042_CR17","doi-asserted-by":"crossref","unstructured":"Brim, B. C. et al. Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7-Expressing CRPC Models. Cancer Res Commun. 5, 1396\u20131408 (2025).","DOI":"10.1158\/2767-9764.CRC-25-0096"},{"key":"64042_CR18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1158\/1078-0432.CCR-20-2344","volume":"27","author":"F Karzai","year":"2021","unstructured":"Karzai, F. et al. Sequential prostate magnetic resonance imaging in newly diagnosed high-risk prostate cancer treated with neoadjuvant enzalutamide is predictive of therapeutic response. Clin. Cancer Res. 27, 429\u2013437 (2021).","journal-title":"Clin. Cancer Res."},{"key":"64042_CR19","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nm.4053","volume":"22","author":"A Kumar","year":"2016","unstructured":"Kumar, A. et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat. Med. 22, 369\u2013378 (2016).","journal-title":"Nat. Med."},{"key":"64042_CR20","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1182\/bloodadvances.2019000702","volume":"3","author":"A Slomp","year":"2019","unstructured":"Slomp, A. et al. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. Blood Adv. 3, 4202\u20134214 (2019).","journal-title":"Blood Adv."},{"key":"64042_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18372-1","volume":"11","author":"E Munkhbaatar","year":"2020","unstructured":"Munkhbaatar, E. et al. MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. Nat. Commun. 11, 4527 (2020).","journal-title":"Nat. Commun."},{"key":"64042_CR22","doi-asserted-by":"publisher","first-page":"19051","DOI":"10.1074\/jbc.M501391200","volume":"280","author":"D Chandra","year":"2005","unstructured":"Chandra, D., Choy, G., Daniel, P. T. & Tang, D. G. Bax-dependent regulation of Bak by voltage-dependent anion channel 2. J. Biol. Chem. 280, 19051\u201319061 (2005).","journal-title":"J. Biol. Chem."},{"key":"64042_CR23","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1158\/1078-0432.CCR-18-0981","volume":"25","author":"JS de Bono","year":"2019","unstructured":"de Bono, J. S. et al. Randomized Phase II study evaluating akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN Loss. Clin. Cancer Res. 25, 928\u2013936 (2019).","journal-title":"Clin. Cancer Res."},{"key":"64042_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","volume":"398","author":"C Sweeney","year":"2021","unstructured":"Sweeney, C. et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet 398, 131\u2013142 (2021).","journal-title":"Lancet"},{"key":"64042_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/cdd.2017.186","volume":"25","author":"J Kale","year":"2018","unstructured":"Kale, J., Osterlund, E. J. & Andrews, D. W. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 25, 65\u201380 (2018).","journal-title":"Cell Death Differ."},{"key":"64042_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07551-w","volume":"9","author":"AE Tron","year":"2018","unstructured":"Tron, A. E. et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat. Commun. 9, 5341 (2018).","journal-title":"Nat. Commun."},{"key":"64042_CR27","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-17-3571","volume":"24","author":"J Welti","year":"2018","unstructured":"Welti, J. et al. Targeting bromodomain and extra-terminal (BET) family proteins in castration-resistant prostate cancer (CRPC). Clin. Cancer Res. 24, 3149\u20133162 (2018).","journal-title":"Clin. Cancer Res."},{"key":"64042_CR28","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1593\/neo.10726","volume":"12","author":"K Park","year":"2010","unstructured":"Park, K. et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12, 590\u2013598 (2010).","journal-title":"Neoplasia"},{"key":"64042_CR29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy, A. et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538, 477\u2013482 (2016).","journal-title":"Nature"},{"key":"64042_CR30","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","volume":"26","author":"J Cidado","year":"2020","unstructured":"Cidado, J. et al. AZD4573 Is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells. Clin. Cancer Res. 26, 922\u2013934 (2020).","journal-title":"Clin. Cancer Res."},{"key":"64042_CR31","doi-asserted-by":"publisher","first-page":"e0234103","DOI":"10.1371\/journal.pone.0234103","volume":"15","author":"S Frame","year":"2020","unstructured":"Frame, S. et al. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. PLoS One 15, e0234103 (2020).","journal-title":"PLoS One"},{"key":"64042_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18368-w","volume":"7","author":"J Dey","year":"2017","unstructured":"Dey, J. et al. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk diffuse Large B-cell Lymphoma to BCL2 inhibition. Sci. Rep. 7, 18007 (2017).","journal-title":"Sci. Rep."},{"key":"64042_CR33","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/jcp.21522","volume":"217","author":"F Fabbri","year":"2008","unstructured":"Fabbri, F. et al. Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells. J. Cell. Physiol. 217, 494\u2013501 (2008).","journal-title":"J. Cell. Physiol."},{"key":"64042_CR34","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s41418-022-01080-2","volume":"30","author":"Y Wang","year":"2023","unstructured":"Wang, Y. & Poon, R. Y. C. MARCH5 regulates mitotic apoptosis through MCL1-dependent and independent mechanisms. Cell. Death. Differ. 30, 753\u2013765 (2023).","journal-title":"Cell. Death. Differ."},{"key":"64042_CR35","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1182\/bloodadvances.2019001393","volume":"4","author":"TA Bloedjes","year":"2020","unstructured":"Bloedjes, T. A. et al. AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma. Blood. Adv. 4, 4151\u20134164 (2020).","journal-title":"Blood. Adv."},{"key":"64042_CR36","doi-asserted-by":"publisher","first-page":"2214465","DOI":"10.1080\/16078454.2023.2214465","volume":"28","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. AKT inhibition sensitizes acute leukemia cells to S63845-induced apoptosis. Hematology 28, 2214465 (2023).","journal-title":"Hematology"},{"key":"64042_CR37","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1038\/s41388-022-02482-9","volume":"41","author":"S Dunn","year":"2022","unstructured":"Dunn, S. et al. AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kbeta\/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors. Oncogene 41, 5046\u20135060 (2022).","journal-title":"Oncogene"},{"key":"64042_CR38","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0092-8674(00)80405-5","volume":"91","author":"SR Datta","year":"1997","unstructured":"Datta, S. R. et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231\u2013241 (1997).","journal-title":"Cell"},{"key":"64042_CR39","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0092-8674(00)81382-3","volume":"87","author":"J Zha","year":"1996","unstructured":"Zha, J., Harada, H., Yang, E., Jockel, J. & Korsmeyer, S. J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87, 619\u2013628 (1996).","journal-title":"Cell"},{"key":"64042_CR40","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/ncb1499","volume":"8","author":"H Kim","year":"2006","unstructured":"Kim, H. et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 8, 1348\u20131358 (2006).","journal-title":"Nat. Cell Biol."},{"key":"64042_CR41","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","volume":"128","author":"KD Mason","year":"2007","unstructured":"Mason, K. D. et al. Programmed anuclear cell death delimits platelet life span. Cell 128, 1173\u20131186 (2007).","journal-title":"Cell"},{"key":"64042_CR42","doi-asserted-by":"publisher","first-page":"4475","DOI":"10.1038\/s41388-018-0268-2","volume":"37","author":"CE Weeden","year":"2018","unstructured":"Weeden, C. E. et al. Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition. Oncogene 37, 4475\u20134488 (2018).","journal-title":"Oncogene"},{"key":"64042_CR43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/0092-8674(95)90411-5","volume":"80","author":"E Yang","year":"1995","unstructured":"Yang, E. et al. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80, 285\u2013291 (1995).","journal-title":"Cell"},{"key":"64042_CR44","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.eururo.2014.10.027","volume":"67","author":"R Ferraldeschi","year":"2015","unstructured":"Ferraldeschi, R. et al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur. Urol. 67, 795\u2013802 (2015).","journal-title":"Eur. Urol."},{"key":"64042_CR45","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl. Acad. Sci. USA 116, 11428\u201311436 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"64042_CR46","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/ng.370","volume":"41","author":"BS Carver","year":"2009","unstructured":"Carver, B. S. et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 41, 619\u2013624 (2009).","journal-title":"Nat. Genet."},{"key":"64042_CR47","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/ng.371","volume":"41","author":"JC King","year":"2009","unstructured":"King, J. C. et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Genet. 41, 524\u2013526 (2009).","journal-title":"Nat. Genet."},{"key":"64042_CR48","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1172\/JCI122819","volume":"129","author":"A Sharp","year":"2019","unstructured":"Sharp, A. et al. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J. Clin. Investig. 129, 192\u2013208 (2019).","journal-title":"J. Clin. Investig."},{"key":"64042_CR49","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1158\/0008-5472.CAN-08-3667","volume":"69","author":"G Attard","year":"2009","unstructured":"Attard, G. et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 69, 2912\u20132918 (2009).","journal-title":"Cancer Res."},{"key":"64042_CR50","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccr.2010.03.018","volume":"17","author":"J Yu","year":"2010","unstructured":"Yu, J. et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17, 443\u2013454 (2010).","journal-title":"Cancer Cell"},{"key":"64042_CR51","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2013.54.3553","volume":"32","author":"HT Wang","year":"2014","unstructured":"Wang, H. T. et al. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J. Clin. Oncol. 32, 3383\u20133390 (2014).","journal-title":"J. Clin. Oncol."},{"key":"64042_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-017-0593-6","volume":"19","author":"PJ Vlachostergios","year":"2017","unstructured":"Vlachostergios, P. J., Puca, L. & Beltran, H. Emerging variants of castration-resistant prostate cancer. Curr. Oncol. Rep. 19, 32 (2017).","journal-title":"Curr. Oncol. Rep."},{"key":"64042_CR53","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/S0959-8049(22)00849-8","volume":"174","author":"S Piha-Paul","year":"2022","unstructured":"Piha-Paul, S. et al. A phase 1\/2, open-label, multicenter study to investigate the safety, pharmacokinetics, and efficacy of fadraciclib (CYC065), an oral CDK2\/9 inhibitor, in subjects with advanced solid tumors and lymphoma. Eur. J. Cancer 174, S17\u2013S18 (2022).","journal-title":"Eur. J. Cancer"},{"key":"64042_CR54","doi-asserted-by":"crossref","unstructured":"Strati, P. et al. P1126: phase 1B\/2A study of AZD4573 (CDK9i) and acalabrutinib in patients (PTS) with relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL). Hemasphere 7, e47925e9 (Suppl) (2023).","DOI":"10.1097\/01.HS9.0000971400.47925.e9"},{"key":"64042_CR55","doi-asserted-by":"publisher","first-page":"CT037","DOI":"10.1158\/1538-7445.AM2018-CT037","volume":"78","author":"KT Do","year":"2018","unstructured":"Do, K. T. et al. Abstract CT037: phase I safety, pharmacokinetic and pharmacodynamic study of CYC065, a cyclin dependent kinase inhibitor, in patients with advanced cancers (NCT02552953). Cancer Res. 78, CT037\u2013CT037 (2018).","journal-title":"Cancer Res."},{"key":"64042_CR56","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1158\/0008-5472.CAN-15-1070","volume":"76","author":"A Baker","year":"2016","unstructured":"Baker, A. et al. The CDK9 Inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of Mll-rearranged acute myeloid leukemia. Cancer Res. 76, 1158\u20131169 (2016).","journal-title":"Cancer Res."},{"key":"64042_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2011.66","volume":"2","author":"G Polier","year":"2011","unstructured":"Polier, G. et al. Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1. Cell Death Dis. 2, e182 (2011).","journal-title":"Cell Death Dis."},{"key":"64042_CR58","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1101\/gad.215855.113","volume":"27","author":"X Wang","year":"2013","unstructured":"Wang, X. et al. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 27, 1351\u20131364 (2013).","journal-title":"Genes Dev."},{"key":"64042_CR59","doi-asserted-by":"crossref","unstructured":"Desai, P. et al. A Phase 1 First-in-human study of the Mcl-1 inhibitor Azd5991 in patients with relapsed\/refractory hematologic malignancies. Clin. Cancer Res. 30, 4844\u20134855 (2024).","DOI":"10.1158\/1078-0432.CCR-24-0028"},{"key":"64042_CR60","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1200\/JCO.2021.39.15_suppl.3015","volume":"39","author":"AW Tolcher","year":"2021","unstructured":"Tolcher, A. W. et al. A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed\/refractory solid tumors: dose escalation results. J. Clin. Oncol. 39, 3015 (2021).","journal-title":"J. Clin. Oncol."},{"key":"64042_CR61","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","volume":"25","author":"S Khan","year":"2019","unstructured":"Khan, S. et al. A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity. Nat. Med. 25, 1938\u20131947 (2019).","journal-title":"Nat. Med."},{"key":"64042_CR62","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1172\/JCI132031","volume":"130","author":"J Mateo","year":"2020","unstructured":"Mateo, J. et al. Genomics of lethal prostate cancer at diagnosis and castration resistance. J. Clin. Investig. 130, 1743\u20131751 (2020).","journal-title":"J. Clin. Investig."},{"key":"64042_CR63","doi-asserted-by":"crossref","unstructured":"Fenor de la Maza, M. D. et al. Immune biomarkers in metastatic castration-resistant prostate cancer. Eur. Urol. Oncol. 5, 659\u2013667 (2022).","DOI":"10.1016\/j.euo.2022.04.004"},{"key":"64042_CR64","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2021.05.030","volume":"80","author":"S Sumanasuriya","year":"2021","unstructured":"Sumanasuriya, S. et al. Elucidating prostate cancer behaviour during treatment via low-pass whole-genome sequencing of circulating tumour DNA. Eur. Urol. 80, 243\u2013253 (2021).","journal-title":"Eur. Urol."},{"key":"64042_CR65","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 161, 1215\u20131228 (2015).","journal-title":"Cell"},{"key":"64042_CR66","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu, J. et al. An Integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173, 400\u2013416.e11 (2018).","journal-title":"Cell"},{"key":"64042_CR67","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.eururo.2021.03.009","volume":"80","author":"S Wilkinson","year":"2021","unstructured":"Wilkinson, S. et al. Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy. Eur. Urol. 80, 746\u2013757 (2021).","journal-title":"Eur. Urol."},{"key":"64042_CR68","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"64042_CR69","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkad1025","volume":"52","author":"M Milacic","year":"2024","unstructured":"Milacic, M. et al. The reactome pathway knowledgebase 2024. Nucleic Acids Res. 52, D672\u2013D678 (2024).","journal-title":"Nucleic Acids Res."},{"key":"64042_CR70","doi-asserted-by":"crossref","unstructured":"Westaby, D. et al. BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity. J. Clin. Investig. 134, e179998 (2024).","DOI":"10.1172\/JCI179998"},{"key":"64042_CR71","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1136\/jcp.48.9.876","volume":"48","author":"S Detre","year":"1995","unstructured":"Detre, S., Saclani Jotti, G. & Dowsett, M. A \u201cquickscore\u201d method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J. Clin. Pathol. 48, 876\u2013878 (1995).","journal-title":"J. Clin. Pathol."},{"key":"64042_CR72","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/sj.bjc.6605554","volume":"102","author":"AH Reid","year":"2010","unstructured":"Reid, A. H. et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br. J. Cancer 102, 678\u2013684 (2010).","journal-title":"Br. J. Cancer"},{"key":"64042_CR73","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","volume":"11","author":"J Welti","year":"2021","unstructured":"Welti, J. et al. Targeting the p300\/CBP Axis in lethal prostate cancer. Cancer Discov. 11, 1118\u20131137 (2021).","journal-title":"Cancer Discov."},{"key":"64042_CR74","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.1158\/0008-5472.CAN-21-3360","volume":"81","author":"V Gil","year":"2021","unstructured":"Gil, V. et al. HER3 Is an actionable target in advanced prostate cancer. Cancer Res 81, 6207\u20136218 (2021).","journal-title":"Cancer Res"},{"key":"64042_CR75","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nature03918","volume":"436","author":"Z Chen","year":"2005","unstructured":"Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725\u2013730 (2005).","journal-title":"Nature"},{"key":"64042_CR76","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1101\/gad.14.8.994","volume":"14","author":"S Marino","year":"2000","unstructured":"Marino, S., Vooijs, M., van Der Gulden, H., Jonkers, J. & Berns, A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 14, 994\u20131004 (2000).","journal-title":"Genes Dev."},{"key":"64042_CR77","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/ni.2418","volume":"13","author":"DP Calado","year":"2012","unstructured":"Calado, D. P. et al. The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. Nat. Immunol. 13, 1092\u20131100 (2012).","journal-title":"Nat. Immunol."},{"key":"64042_CR78","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.stem.2007.03.002","volume":"1","author":"Y Ruzankina","year":"2007","unstructured":"Ruzankina, Y. et al. Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. Cell Stem Cell 1, 113\u2013126 (2007).","journal-title":"Cell Stem Cell"},{"key":"64042_CR79","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nprot.2016.006","volume":"11","author":"J Drost","year":"2016","unstructured":"Drost, J. et al. Organoid culture systems for prostate epithelial and cancer tissue. Nat. Protoc. 11, 347\u2013358 (2016).","journal-title":"Nat. Protoc."},{"key":"64042_CR80","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1073\/pnas.1311846111","volume":"111","author":"LA Mathews Griner","year":"2014","unstructured":"Mathews Griner, L. A. et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc. Natl. Acad. Sci. USA 111, 2349\u20132354 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"64042_CR81","unstructured":"Lin, G. L. et al. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Sci. Transl. Med. 11, eaaw0064 (2019)."},{"key":"64042_CR82","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","volume":"20","author":"S Zheng","year":"2022","unstructured":"Zheng, S. et al. SynergyFinder Plus: toward better interpretation and annotation of drug combination screening datasets. Genom. Proteom. Bioinforma. 20, 587\u2013596 (2022).","journal-title":"Genom. Proteom. Bioinforma."},{"key":"64042_CR83","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav, B., Wennerberg, K., Aittokallio, T. & Tang, J. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput. Struct. Biotechnol. J. 13, 504\u2013513 (2015).","journal-title":"Comput. Struct. Biotechnol. J."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64042-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64042-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64042-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:08:27Z","timestamp":1760000907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64042-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["64042"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-64042-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"7 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.M.J.-V., D.W., I.F., A.d.H.V., A.P., W.Y., G.S., D.B., B.G., C.B., S.M., L.B., W.Z., A.J.N., J.W., J.R., R.P., A.F., M.C., R.R., S.D., J.T., E.H., M.V., J.N., K.L., A.S., F.R., S.C., J.S.d.B. and A.Sharp are employees of the ICR, which has a commercial interest in abiraterone, PARP inhibition in DNA repair defective cancers, and PI3K\/AKT pathway inhibitors (no personal income). A.G.S. reports that the National Cancer Institute (NCI) has a Cooperative Research and Development Agreement (CRADA) with Astellas. Resources are provided by this CRADA to the NCI. A.G.S. gets no personal funding from this CRADA but is the primary investigator of the CRADA. J.S.d.B. has served on advisory boards and received fees from many companies, including Amgen, Astra Zeneca, Bayer, Bioxcel Therapeutics, Daiichi, Genentech\/Roche, GSK, Merck Serono, Merck Sharp & Dohme, Pfizer, and Sanofi Aventis. He is an employee of the ICR, which has received funding or other support for his research work from AZ, Astellas, Bayer, Cellcentric, Daiichi, Genentech, Genmab, GSK, Janssen, Merck Serono, MSD, Menarini\/Silicon Biosystems, Orion, Sanofi Aventis, Sierra Oncology, Taiho, Pfizer, Vertex. J.S.d.B. was named as an inventor, with no financial interest, for patent 8,822,438, submitted by Janssen, that covers the use of abiraterone acetate with corticosteroids. J.S.d.B. has been the CI\/PI of many industry-sponsored clinical trials. A.Sharp has received travel support from Sanofi, Roche-Genentech and Nurix, and speaker honoraria from Astellas Pharma and Merck Sharp & Dohme. He has served as an advisor to DE Shaw Research, CHARM Therapeutics, Ellipses Pharma and Droia Ventures. A.Sharp has been the CI\/PI of industry-sponsored clinical trials. The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8806"}}